Lantern Pharma Announces EMA Clearance Of An Investigator-Initiated Phase 1b/2 Clinical Trial Of LP-184 In Advanced, Recurrent Bladder Cancer
Lantern Pharma Inc LTRN
$2.63
▼ -0.75%
($-0.02)
🎈 Low Float
🎢 High Beta
🗓️ Earnings Next Week
Open
$2.72
Prev Close
$2.65
Day Range
$2.57 – $2.87
52W Range
$1.11 – $5.74
Market Cap
$33.56M
Beta
2.33
EPS (TTM)
$-1.45
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-06-11 |
| Shares Out. | 12,760,000 |
| Website | lanternpharma.com/ ↗ |
| Phone | 19722771136 |
| Employees | 16 |
| Net Income | -$3.3M |
| Free Cash Flow | -$15.1M |
| Total Assets | $7.2M |
| Total Liabilities | $3.8M |
| Equity | $3.4M |
About Lantern Pharma Inc
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Lantern Pharma Inc is a publicly traded company under the ticker symbol LTRN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)